secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058730
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica Q1 net income $0.1M; CARPO Phase 2b enrollment completed; cash into 2H 2025
--------------------------------------------------------------------------------

- Net income of $0.1M ($0.01/share) driven by $5.6M non-cash gain on warrant liability, offsetting $5.8M operating loss.
- Cash & equivalents $25.7M as of March 31, 2024; expected to fund operations into second half of 2025.
- Phase 2b CARPO trial (Auxora in acute pancreatitis) fully enrolled at 216 patients; topline data expected in Q2 2024.
- Phase 2 KOURAGE trial (Auxora in severe AKI with respiratory failure) cleared by FDA; first patient enrollment expected Q2 2024.
- Private placement raised up to ~$54M ($20.4M upfront, ~$33.1M warrants) to support ongoing and planned trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/0000950170-24-058730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/calc-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer